Aquestive Therapeutics IncNASDAQ:AQST
- LAST PRICE2.6600
- TODAY'S CHANGE (%)0.0700 (2.7027%)
- Bid / Lots2.6500/ 22
- Ask / Lots2.6600/ 13
- Open / Previous Close2.6000 / 2.5900
- Day Range
- 52 Week Range
- Volume271,954
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AQST |
|---|---|---|
| 09:32 ET | 31626 | 2.59 |
| 09:34 ET | 2700 | 2.58 |
| 09:36 ET | 1447 | 2.57 |
| 09:38 ET | 2155 | 2.58 |
| 09:39 ET | 629 | 2.58 |
| 09:41 ET | 15611 | 2.59 |
| 09:43 ET | 19534 | 2.605 |
| 09:45 ET | 3016 | 2.605 |
| 09:48 ET | 1917 | 2.595 |
| 09:50 ET | 2015 | 2.595 |
| 09:52 ET | 1309 | 2.6 |
| 09:54 ET | 5350 | 2.605 |
| 09:56 ET | 9608 | 2.605 |
| 09:57 ET | 1300 | 2.6083 |
| 09:59 ET | 6848 | 2.595 |
| 10:01 ET | 5582 | 2.595 |
| 10:03 ET | 6389 | 2.615 |
| 10:06 ET | 2694 | 2.625 |
| 10:08 ET | 13707 | 2.62 |
| 10:10 ET | 7734 | 2.64 |
| 10:12 ET | 6932 | 2.655 |
| 10:14 ET | 36131 | 2.645 |
| 10:15 ET | 11286 | 2.655 |
| 10:17 ET | 9952 | 2.665 |
| 10:19 ET | 22491 | 2.6501 |
| 10:21 ET | 703 | 2.66 |
Yesterday
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism, from 8:00AM ET on Thursday Jun 27, 2024 by Dow Jones
8:00AM ET on Thursday Jun 27, 2024 by Dow Jones
Jun 26, 2024
DJ Aquestive Therapeutics Price Target Maintained With a $9.00/Share by JMP Securities, from 12:13PM ET on Wednesday Jun 26, 2024 by Dow Jones
12:13PM ET on Wednesday Jun 26, 2024 by Dow Jones
Jun 25, 2024
Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm(TM) (epinephrine) Sublingual Film, from 8:00AM ET on Tuesday Jun 25, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 25, 2024 by Dow Jones
Jun 18, 2024
Aquestive Therapeutics to Join the Russell 3000(R) and Russell 2000(R) Indexes Effective June 28, 2024, from 8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 5, 2024
DJ Aquestive Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co., from 7:24AM ET on Wednesday Jun 05, 2024 by Dow Jones
7:24AM ET on Wednesday Jun 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aquestive Therapeutics Inc | 220.3M | -6.2x | --- |
Sanara Medtech Inc | 241.6M | -47.7x | --- |
Dr Reddy's Laboratories Ltd | 12.4B | 19.1x | +24.18% |
OptiNose Inc | 144.5M | -4.0x | --- |
Integrated Biopharma Inc | 6.0M | -49.3x | --- |
Qilian International Holding Group Ltd | 21.8M | -2.9x | --- |
Company Information
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.
Contact Information
- Headquarters
- 30 Technology DrWARREN, NJ, United States 07059-5166
- Phone
- 908-941-1900
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Gregory Brown
- President, Chief Executive Officer, Director
- Daniel Barber
- Independent Vice Chairman of the Board
- John Cochran
- Chief Financial Officer
- A. Ernest Toth
- Chief Operating Officer
- Cassie Jung
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $220.3M |
|---|---|
Revenue (TTM) | $51.5M |
Shares Outstanding | 91.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.79 |
EPS | $-0.43 |
Book Value | $-1.55 |
P/E Ratio | -6.2x |
Price/Sales (TTM) | 4.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -39.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
